LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MCG (100mcgmL) Singapūra - angļu - HSA (Health Sciences Authority)

lyxumia solution for injection in pre-filled pen 20mcg (100mcgml)

sanofi-aventis singapore pte. ltd. - lixisenatide - injection, solution - 100mcg/ml - lixisenatide 100mcg/ml

APIDRA 100 Unitsml Solution for Injection in vial Singapūra - angļu - HSA (Health Sciences Authority)

apidra 100 unitsml solution for injection in vial

sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg - insulin glulisine 3.49 mg

PLAQUENIL TABLET 200 mg (White) Singapūra - angļu - HSA (Health Sciences Authority)

plaquenil tablet 200 mg (white)

sanofi-aventis singapore pte. ltd. - hydroxychloroquine sulphate - tablet, film coated - 200 mg - hydroxychloroquine sulphate 200.0 mg

ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MGML Singapūra - angļu - HSA (Health Sciences Authority)

zaltrap concentrate for solution for infusion 25 mgml

sanofi-aventis singapore pte. ltd. - aflibercept - infusion, solution concentrate - 25.0 mg/ml - aflibercept 25.0 mg/ml

Podevta solution for Injection in cartridge 100 Unitsml Singapūra - angļu - HSA (Health Sciences Authority)

podevta solution for injection in cartridge 100 unitsml

sanofi-aventis singapore pte. ltd. - insulin glargine - injection, solution - 100units/ml(10.9134mg/3ml) - insulin glargine 100units/ml(10.9134mg/3ml)

MAALOX SUGAR-FREE CHEWABLE TABLETS 400/400 Milligram Tablets Chewable Īrija - angļu - HPRA (Health Products Regulatory Authority)

maalox sugar-free chewable tablets 400/400 milligram tablets chewable

sanofi-aventis ireland limited t/a sanofi - aluminium oxide hydrated, magnesium hydroxide - tablets chewable - 400/400 milligram - combinations - for the relief of the symptoms of dyspepsia.

Lyxumia Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

lyxumia

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Lyxumia Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

lyxumia

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Lyxumia Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

lyxumia

sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

ORIFER F TABLET Kanāda - angļu - Health Canada

orifer f tablet

sanofi-aventis canada inc - zinc (zinc sulfate); vitamin a acetate; vitamin d3; ascorbic acid; thiamine mononitrate; pyridoxine hydrochloride; vitamin b2; nicotinamide; folic acid; iron (ferrous sulfate); calcium (calcium carbonate) - tablet - 20mg; 1600unit; 200unit; 50mg; 0.75mg; 9mg; 1mg; 6mg; 0.8mg; 60mg; 125mg - zinc (zinc sulfate) 20mg; vitamin a acetate 1600unit; vitamin d3 200unit; ascorbic acid 50mg; thiamine mononitrate 0.75mg; pyridoxine hydrochloride 9mg; vitamin b2 1mg; nicotinamide 6mg; folic acid 0.8mg; iron (ferrous sulfate) 60mg; calcium (calcium carbonate) 125mg - vitamins & minerals